Why BioNTech Stock Shot Higher on Wednesday

What happened

Shares of BioNTech (NASDAQ: BNTX) climbed sharply higher on Wednesday, gaining as much as 11% earlier in the session, though the stock ended the trading day up 10.3%.

The biotechnology company is known for partnering with Pfizer (NYSE: PFE) to co-develop the BNT162b2 COVID-19 vaccine. BioNTech road Pfizer's coattails higher today as the company reported strong sales of its vaccine and raised its full-year forecast as a result.

A healthcare professional using a syringe to draw medication from vial.

Image source: Getty Images.

So what

Pfizer reported robust second-quarter results, with the vaccine generating $7.9 billion -- or roughly 42% of the company's revenue. The pharmaceutical giant also boosted its full-year guidance and is now expecting revenue of approximately $33.5 billion from the vaccine, up from its previous forecast of $26 billion. Needless to say, the vaccine gave both stocks a shot in the arm.

Other news likely contributed to BioNTech's rise today. The Centers for Disease Control (CDC) recommended on Tuesday that children and fully vaccinated adults should begin wearing mask indoors again in areas with high COVID-19 transmission rates. This comes on the heels of a spike in the number of new cases, driven higher by the continued emergence of the delta variant as the dominant strain.

Now what

The rising number of COVID-19 cases is increasing the chorus of calls for more people to get vaccinated. Additionally, Pfizer has been making the case for a third dose of the vaccine to boost immunity even further and is planning to submit additional data to U.S. regulatory agencies as early as August.

While regulators have yet to be convinced that an additional dose is needed, Pfizer and BioNTech could eventually earn billions of dollars if a third dose is eventually deemed necessary.

10 stocks we like better than BioNTech SE
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and BioNTech SE wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

Danny Vena has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More